Compare Bristol-Myers Squibb Co (BMY) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Western Union Co — how do they compare? Bristol-Myers Squibb Co trades at $58.35 (market cap $116.30B), while Western Union Co trades at $8.01 (market cap $2.46B). The key difference: Bristol-Myers Squibb Co is far larger — about 47.3× Western Union Co's market cap, and Western Union Co pays the higher dividend (11.93%). Which is the better fit depends on your goals.
| BMY | WU | |
|---|---|---|
Market Cap | $116.30B | $2.46B |
Sector | Health | Technology |
52-Week High | $62.37 | $10.28 |
52-Week Low | $42.60 | $7.04 |
Enterprise Value | $152.24B | $2.16B |
Dividend Yield | 4.42% | 11.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Western Union (WU) trades at $7.87, up 0.38% with a bullish technical signal. The stock shows attractive valuation with P/E of 5.79 and P/S of 0.63, supported by strong profitability metrics including 47.66% ROE. Recent earnings show mixed performance with Q1 2026 miss but Q3 and Q4 2025 beats. The company maintains strategic partnerships with Total Wireless and digital expansion initiatives, though revenue has declined from $4.5B in 2022 to $4.05B in 2025.
WU presents a value opportunity with deep valuation discounts but faces revenue headwinds and competitive pressures. The 11.5% dividend yield provides income support, though high debt levels and declining net income margins warrant caution. Analyst consensus remains mixed with 58% hold ratings, reflecting balanced risk-reward amid digital transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
